Green Earth Institute Co., Ltd.【JP:9212】Stock Price

Green Earth Institute is a technology-driven venture that aims to replace petroleum-based chemicals with biomass-derived alternatives such as agricultural and food waste, using proprietary fermentation technology based on Corynebacterium bacteria as its core. The company operates through multiple business models: contract research and development, licensing of developed bacterial strains and production processes to partners, contract manufacturing and sales of its own products, and technology packages that bundle equipment, design, and know-how.

Key customers include chemical manufacturers, raw material producers for food, feed, and pharmaceuticals, companies seeking to produce biochemicals, and engineering firms specializing in equipment. The company's revenue model transitions from contract research income in the development stage to upfront licensing fees and ongoing royalties during commercialization, followed by product sales revenue.

The core of operations is pipeline management organized in Stages 0-3, where projects progress through candidate selection, bacterial strain and process development in the laboratory, pilot testing and validation, and plant implementation and product sales. The company is equipped with demonstration facilities, preprocessing and purification equipment, fermentation tanks up to 3,000 liters in capacity, and scale-up support through numerical analysis, enabling it to provide comprehensive services from experimentation through pilot testing to commercialization support.

The company aims to grow by leveraging its proprietary fermentation technology based on Corynebacterium bacteria to replace petroleum-derived chemicals with those derived from non-food biomass such as agricultural and food waste. Its business model centers on three revenue pillars: contract research and development as the entry point, licensing of developed bacterial strains and production processes to partners, contract manufacturing and sales by the company itself, and technology packages that bundle equipment, design, and operational expertise. The strategy involves a phased transition of revenue from near-term contract income to license upfront fees and royalties, and ultimately to product sales. Recently, the company achieved sales exceeding 1 billion yen in fiscal 2025 and secured operating profits exceeding 100 million yen including research and development subsidies, with plans to pursue further sales expansion and cash flow maximization over the medium to long term.

Priority investment areas include building a pipeline across diverse feedstocks: biofoundry services, ethanol from woody biomass, biofuels and resin precursors from paper industry materials, biochemicals from palm residue and food/agricultural waste, next-generation proteins from rice, and chemicals derived from CO2. The company differentiates itself through end-to-end expertise spanning bacterial strain development through pilot and commercialization phases. Its competitive strengths include demonstration facilities such as fermentation tanks up to 3,000 liters, preprocessing and purification equipment, and numerical analysis capabilities for scale-up support. This positions the company to focus on large-scale, capital-intensive projects with recurring revenue streams, thereby establishing a stable earnings foundation.

For new market development and business expansion over the next three years, the company prioritizes commercializing biofuel production technology and non-food biomass-derived bioresin precursors, and advancing local commercialization through partnerships with overseas companies. Specifically, the company aims to expand royalties from five amino acid variants already licensed and next-generation rice-derived proteins already commercialized, while pursuing joint investments for overseas feedstock sourcing and cost reduction, collaborations with engineering firms, and participation in large-scale projects involving government and local authorities. Revenue will be scaled through both licensing income and direct sales. To support growth, the company will progressively strengthen internal controls, enhance talent recruitment, and expand research facilities and testing equipment.

Technology innovation is the company's highest priority, with continued investment in Corynebacterium strain improvement, fermentation process efficiency gains, and refinement of feedstock preprocessing and downstream purification technologies. To provide end-to-end support from lab development through pilot testing to plant deployment, the company operates demonstration lines and accumulates scale-up expertise through numerical simulation, packaging these as technology offerings to reduce near-term implementation barriers. The company has set numerical targets for manufacturing cost reduction and product recovery rate improvement, aiming to stabilize earnings through royalty increases tied to licensee sales growth.